Valeant Pharma (VRX) Posts Mixed Q4
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Valeant Announces Fourth-Quarter And Full-Year 2017 Results And Provides 2018 Guidance
February 28, 2018 7:00 AM ESTLAVAL, Quebec, Feb. 28, 2018 /PRNewswire/ --
Fourth-Quarter 2017 Financial Results Revenues of $2.163 Billion GAAP Net Income of $513 Million GAAP Cash Flow from Operations of $578 Million Adjusted EBITDA (non-GAAP)1 of $875 Million Full-Year 2017 Financial Results Revenues of $8.724 Billion GAAP Net Income of $2.404 Billion GAAP Cash Flow from Operations of $2.290 Billion Adjusted EBITDA (non-GAAP) of $3.638 BillionValeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX:... More
